<?xml version='1.0' encoding='utf-8'?>
<document id="29777022"><sentence text="Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition."><entity charOffset="38-54" id="DDI-PubMed.29777022.s1.e0" text="Coproporphyrin I" /></sentence><sentence text="In a recent study, limited to South Asian Indian subjects (n = 12), coproporphyrin (CP) I and CPIII demonstrated properties appropriate for an organic anion-transporting polypeptide (OATP) 1B endogenous probe"><entity charOffset="68-82" id="DDI-PubMed.29777022.s2.e0" text="coproporphyrin" /></sentence><sentence text=" The current studies were conducted in healthy volunteers of mixed ethnicities, including black, white, and Hispanic subjects, to better understand the utility of these biomarkers in broader populations" /><sentence text=" After oral administration with 600 mg rifampin, AUC(0-24h) values were 2"><entity charOffset="39-47" id="DDI-PubMed.29777022.s4.e0" text="rifampin" /></sentence><sentence text="8-, 3" /><sentence text="7-, and 3" /><sentence text="6-fold higher than predose levels for CPI and 2" /><sentence text="6-, 3" /><sentence text="1-, and 2" /><sentence text="4-fold higher for CPIII, for the three populations, respectively" /><sentence text=" These changes in response to rifampin were consistent with previous results"><entity charOffset="30-38" id="DDI-PubMed.29777022.s11.e0" text="rifampin" /></sentence><sentence text=" The sensitivity toward OATP1B inhibition was also investigated by evaluating changes of plasma CP levels in the presence of diltiazem and itraconazole [administered as part of an unrelated drug-drug interaction (DDI) investigation], two compounds that were predicted to have minimal inhibitory effect on OATP1B"><entity charOffset="139-151" id="DDI-PubMed.29777022.s12.e0" text="itraconazole" /></sentence><sentence text=" Administration of diltiazem and itraconazole did not increase plasma CPI and CPIII concentrations relative to prestudy levels, in agreement with predictions from in vitro parameters"><entity charOffset="19-28" id="DDI-PubMed.29777022.s13.e0" text="diltiazem" /><entity charOffset="33-45" id="DDI-PubMed.29777022.s13.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.29777022.s13.e0" e2="DDI-PubMed.29777022.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29777022.s13.e0" e2="DDI-PubMed.29777022.s13.e1" /></sentence><sentence text=" Additionally, the basal CP concentrations in subjects with SLCO1B1 c"><entity charOffset="60-67" id="DDI-PubMed.29777022.s14.e0" text="SLCO1B1" /></sentence><sentence text="521TT genotype were comparable to those with SLCO1B1 c" /><sentence text="521TC genotype, similar to studies with probe substrates" /><sentence text=" However, subjects with SLCO1B1 c"><entity charOffset="24-31" id="DDI-PubMed.29777022.s17.e0" text="SLCO1B1" /></sentence><sentence text="388AG and c" /><sentence text="388GG genotypes (i" /><sentence text="e" /><sentence text=", increased OATP1B1 transport activity for certain substrates) had lower concentrations of CPI than those with SLCO1B1 c"><entity charOffset="111-118" id="DDI-PubMed.29777022.s21.e0" text="SLCO1B1" /></sentence><sentence text="388AA" /><sentence text=" Collectively, these findings provide further evidence supporting the translational value of CPI and CPIII as suitable endogenous clinical probes to gauge OATP1B activity and potential for OATP1B-mediated DDIs" /><sentence text="" /></document>